These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34991440)

  • 1. Non-parametric synergy modeling of chemical compounds with Gaussian processes.
    Shapovalova Y; Heskes T; Dijkstra T
    BMC Bioinformatics; 2022 Jan; 23(1):14. PubMed ID: 34991440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive Dose Response Models: Defining Synergy.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2019; 10():1384. PubMed ID: 31849651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Dose Response Models: Explicit Formulation and the Loewe Additivity Consistency Condition.
    Lederer S; Dijkstra TMH; Heskes T
    Front Pharmacol; 2018; 9():31. PubMed ID: 29467650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
    Meletiadis J; Verweij PE; TeDorsthorst DT; Meis JF; Mouton JW
    Med Mycol; 2005 Mar; 43(2):133-52. PubMed ID: 15832557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug interaction: focusing on response surface models.
    Lee SI
    Korean J Anesthesiol; 2010 May; 58(5):421-34. PubMed ID: 20532049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism.
    Kashif M; Andersson C; Mansoori S; Larsson R; Nygren P; Gustafsson MG
    Oncotarget; 2017 Nov; 8(61):103952-103967. PubMed ID: 29262612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical detection of synergy: New methods and a comparative study.
    Thas O; Tourny A; Verbist B; Hawinkel S; Nazarov M; Mutambanengwe K; Bijnens L
    Pharm Stat; 2022 Mar; 21(2):345-360. PubMed ID: 34608741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theory of synergistic effects: Hill-type response surfaces as 'null-interaction' models for mixtures.
    Schindler M
    Theor Biol Med Model; 2017 Aug; 14(1):15. PubMed ID: 28768512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is synergy? The Saariselkä agreement revisited.
    Tang J; Wennerberg K; Aittokallio T
    Front Pharmacol; 2015; 6():181. PubMed ID: 26388771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Introduction to Terminology and Methodology of Chemical Synergy-Perspectives from Across Disciplines.
    Roell KR; Reif DM; Motsinger-Reif AA
    Front Pharmacol; 2017; 8():158. PubMed ID: 28473769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical assessment and visualization of synergies for large-scale sparse drug combination datasets.
    Amzallag A; Ramaswamy S; Benes CH
    BMC Bioinformatics; 2019 Feb; 20(1):83. PubMed ID: 30777010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple test for synergy for a small number of combinations.
    Novick SJ
    Stat Med; 2013 Dec; 32(29):5145-55. PubMed ID: 23904140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. bayesynergy: flexible Bayesian modelling of synergistic interaction effects in in vitro drug combination experiments.
    Rønneberg L; Cremaschi A; Hanes R; Enserink JM; Zucknick M
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34308471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy evaluation of non-normalizable dose-response data: Generalization of combination index for the linear effect of drugs.
    Novotný B; Nagy M; Kurin E
    Pharm Stat; 2021 Nov; 20(6):982-989. PubMed ID: 33764621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Methods for Quantifying Drug Synergism.
    Ma J; Motsinger-Reif A
    Proteom Bioinform; 2019 Jul; 1(2):43-48. PubMed ID: 32043089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling synergistic effects by using general Hill-type response surfaces describing drug interactions.
    Schindler M
    Sci Rep; 2022 Jun; 12(1):10524. PubMed ID: 35732854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solving the Problem of Assessing Synergy and Antagonism for Non-Traditional Dosing Curve Compounds Using the DE/ZI Method: Application to Nrf2 Activators.
    Repash EM; Pensabene KM; Palenchar PM; Eggler AL
    Front Pharmacol; 2021; 12():686201. PubMed ID: 34163365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.
    Meletiadis J; Mouton JW; Meis JF; Verweij PE
    Antimicrob Agents Chemother; 2003 Jan; 47(1):106-17. PubMed ID: 12499177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model.
    Yadav B; Wennerberg K; Aittokallio T; Tang J
    Comput Struct Biotechnol J; 2015; 13():504-13. PubMed ID: 26949479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of null models for combination drug therapy reveals Hand model as biochemically most plausible.
    Sinzger M; Vanhoefer J; Loos C; Hasenauer J
    Sci Rep; 2019 Feb; 9(1):3002. PubMed ID: 30816136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.